Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
English (International)
A Almirall SA
A
Closed
SectorHealthcare
10.74 0.37
Overview
Share price change
24h
Min
10.68
Max
10.8
Income | 24M 22M |
|---|---|
Sales | 28M 286M |
P/E Sector Avg | 96.546 50.291 |
EPS | 0.1 |
Dividend yield | 1.73 |
Profit margin | 7.55 |
Employees | 2,026 |
EBITDA | 3.9M 45M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +14.06% upside |
Dividend yield Sector Avg | 1.73% 2.40% |
|---|---|
Next Earnings | 25 Jul 2025 |
Market Cap | 347M 2.3B |
|---|---|
Previous open | 10.37 |
Previous close | 10.74 |
News Sentiment
By Acuity
50%
50%
165 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Almirall SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Almirall SA Forecast
Price Target
By TipRanks
14.06% upside
12 Months Forecast
Average 12.25 EUR 14.06%
High 12.5 EUR
Low 12 EUR
Based on 2 Wall Street analysts offering 12 month price targets forAlmirall SA - Dist in the last 3 months.
Sentiment
By Acuity
165 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
